About New Investors
Nextech Venture is a global healthcare investment manager located in Zurich, Switzerland. The firm manages three healthcare venture funds (USD 137M), and has recently launched the world's first oncology-focused fund. With its unique oncology-focused fund, Nextech Venture is a dedicated investor in leading oncology companies developing cancer drugs in Europe, the U.S. and Asia. Nextech Venture benefits from the support of an active and committed Scientific Advisory Board of highly influential oncology advisors. Nextech Venture organizes the Global Oncology Venture Event which is held annually in major cities around the globe. For more information, visit http://www.nextechventure.com.
Arcus Ventures consists of a team of professionals with experience in clinical oncology and academic medicine, drug development, hospital management, healthcare industry consulting and private equity. Arcus Ventures is dedicated to investing in oncology focused companies with innovative biopharmaceuticals and or new drug delivery product(s) that have pre-marketing approval and service companies with revenue. For more information, visit http://www.arcusventures.com.
Innovis Investments, located in Irvine, California and Brisbane,
Australia, manages and advises two life science funds with focus on private
and public companies in Biotechnology, Pharmaceuticals and Healthcare.
Innovis Investments has a diverse and integrated team with a strong
operational presence in the U.S. and Pacific Rim countries where half of
its portfolio companies are located. Innovis
|SOURCE MacroGenics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved